Christina M van der Beek1, Emanuel E Canfora2, Anna M Kip3, Stefan H M Gorissen4, Steven W M Olde Damink5, Hans M van Eijk6, Jens J Holst7, Ellen E Blaak8, Cornelis H C Dejong9, Kaatje Lenaerts10. 1. Top Institute Food and Nutrition, Wageningen, the Netherlands; Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: k.vanderbeek@maastrichtuniversity.nl. 2. Top Institute Food and Nutrition, Wageningen, the Netherlands; Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: emanuel.canfora@maastrichtuniversity.nl. 3. Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: m.kip@maastrichtuniversity.nl. 4. Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: stefan.gorissen@maastrichtuniversity.nl. 5. Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands; Department of HPB Surgery and Liver Transplantation, Institute of Liver and Digestive Health, University College London, Rowland Hill Street, London NW3 2PF, United Kingdom. Electronic address: steven.oldedamink@maastrichtuniversity.nl. 6. Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: hmh.vaneijk@maastrichtuniversity.nl. 7. NNF Center for Basic Metabolic Research, Copenhagen, Blegdamsvej 3A, Copenhagen 2200, Denmark; Department of Biomedical Sciences, University of Copenhagen, Nørregade 10, 1165 Copenhagen, Denmark. Electronic address: jjholst@sund.ku.dk. 8. Top Institute Food and Nutrition, Wageningen, the Netherlands; Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: e.blaak@maastrichtuniversity.nl. 9. Top Institute Food and Nutrition, Wageningen, the Netherlands; Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands; Department of Surgery, Universitätsklinikum Aachen, Pauwelsstraße 30, 52074 Aachen, Germany. Electronic address: chc.dejong@mumc.nl. 10. Top Institute Food and Nutrition, Wageningen, the Netherlands; Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands. Electronic address: kaatje.lenaerts@maastrichtuniversity.nl.
Abstract
BACKGROUND AND AIMS: Human gut microbiota play an important role in maintaining human health. Dietary fibers, i.e. prebiotics, are fermented by human gut microbiota into the short-chain fatty acids (SCFAs) acetate, propionate, and butyrate. SCFAs promote fat oxidation and improve metabolic health. Therefore, the prebiotic inulin might be an effective dietary strategy to improve human metabolism. We aimed to investigate the acute metabolic effects of ingesting inulin compared with digestible carbohydrates and to trace inulin-derived SCFAs using stable isotope tracer methodology. METHODS: In a double-blind, randomized, placebo-controlled crossover design, 14 healthy, overweight to obese men consumed a high-fat milkshake containing A) 24 g inulin of which 0.5 g was U-13C-inulin (INU) or B) 24 g maltodextrin placebo (PLA), with a wash-out period of at least five days. Fat oxidation was measured via an open-circuit ventilated hood and blood samples were collected up to 7 h after ingestion. Plasma, breath, and fecal samples were collected, and appetite and satiety scores were assessed. RESULTS:Fat oxidation increased in the early postprandial phase (0-3 h), and both plasma glucose and insulin were lower after INU ingestion compared with PLA (all P < 0.05). Plasma free fatty acids were higher in the early, and lower in the late postprandial period after INU ingestion. Inulin was fermented into SCFAs as indicated by higher plasma acetate concentrations after INU compared with PLA (P < 0.05). In addition, we found continuous increases in plasma 13C-SCFA enrichments (P < 0.05 from t = 120 onwards) and breath 13CO2 enrichments after INU intake. There were no effects on plasma triglycerides, free glycerol, satiety hormones GLP-1 and PYY, and appetite and satiety scores. CONCLUSIONS: Ingestion of the prebiotic inulin improves fat oxidation and promotes SCFA production in overweight to obese men. Overall, replacing digestible carbohydrates with the fermentable inulin may favor human substrate metabolism. CLINICAL TRIAL REGISTRY: The trial was registered at clinicaltrials.gov under number NCT02009670.
RCT Entities:
BACKGROUND AND AIMS: Human gut microbiota play an important role in maintaining human health. Dietary fibers, i.e. prebiotics, are fermented by human gut microbiota into the short-chain fatty acids (SCFAs) acetate, propionate, and butyrate. SCFAs promote fat oxidation and improve metabolic health. Therefore, the prebiotic inulin might be an effective dietary strategy to improve human metabolism. We aimed to investigate the acute metabolic effects of ingesting inulin compared with digestible carbohydrates and to trace inulin-derived SCFAs using stable isotope tracer methodology. METHODS: In a double-blind, randomized, placebo-controlled crossover design, 14 healthy, overweight to obesemen consumed a high-fat milkshake containing A) 24 g inulin of which 0.5 g was U-13C-inulin (INU) or B) 24 g maltodextrin placebo (PLA), with a wash-out period of at least five days. Fat oxidation was measured via an open-circuit ventilated hood and blood samples were collected up to 7 h after ingestion. Plasma, breath, and fecal samples were collected, and appetite and satiety scores were assessed. RESULTS: Fat oxidation increased in the early postprandial phase (0-3 h), and both plasma glucose and insulin were lower after INU ingestion compared with PLA (all P < 0.05). Plasma free fatty acids were higher in the early, and lower in the late postprandial period after INU ingestion. Inulin was fermented into SCFAs as indicated by higher plasma acetate concentrations after INU compared with PLA (P < 0.05). In addition, we found continuous increases in plasma 13C-SCFA enrichments (P < 0.05 from t = 120 onwards) and breath13CO2 enrichments after INU intake. There were no effects on plasma triglycerides, free glycerol, satiety hormones GLP-1 and PYY, and appetite and satiety scores. CONCLUSIONS: Ingestion of the prebiotic inulin improves fat oxidation and promotes SCFA production in overweight to obesemen. Overall, replacing digestible carbohydrates with the fermentable inulin may favor human substrate metabolism. CLINICAL TRIAL REGISTRY: The trial was registered at clinicaltrials.gov under number NCT02009670.
Authors: Miquell O Miller; Purna C Kashyap; Sarah L Becker; Ryan M Thomas; Richard A Hodin; George Miller; Mautin Hundeyin; Smruti Pushalkar; Deirdre Cohen; Deepak Saxena; Benjamin D Shogan; Gareth J Morris-Stiff Journal: J Gastrointest Surg Date: 2021-07 Impact factor: 3.452
Authors: Jingjie Du; Ahmed A Zayed; Kristina A Kigerl; Kylie Zane; Matthew B Sullivan; Phillip G Popovich Journal: mSystems Date: 2021-05-11 Impact factor: 6.496